shrimps disease diagnostic Market Metrics & Forecast Analysis 2033

shrimps disease diagnostic by Application (Fisheries, Aquaculture Laboratories, Marine Laboratories, Education and Research Institutes, Others), by Types (WSSV (White Spot Syndrome Virus), TSV (Taura Syndrome Virus), YHV/GAV (Yellow Head/Gill Associated Virus), IHHNV (Infectious Hypodermal and Hematopoietic Virus), HPV (Hepatopancreatic Parvovirus), MBV (Monodon Baculovirus), IMNV (Infectious Myonecrosis Virus), NHP-B (Necrotising Hepatopancreatitis Bacteria), MoV (Mourilyan Virus), Early Mortality Syndrome (EMS)), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

shrimps disease diagnostic Market Overview

Shrimp disease diagnostic market encompasses analytical solutions—such as PCR‑based kits, ELISA assays, and rapid lateral‑flow tests—used to detect viral, bacterial and parasitic pathogens in farmed shrimp. The market is critical for safeguarding global aquaculture productivity and food security. The shrimp disease diagnostic market size was estimated at approximately USD 220 million in 2025, and a robust growth outlook projects the market to reach USD 410 million by 2033, reflecting a CAGR of about 7.2% over the forecast period. Key macro drivers include escalating shrimp production in Asia, heightened disease outbreaks (e.g., WSSV, IHHNV), stricter bio‑security regulations, and rapid advances in molecular testing technologies.

Loading chart…

Three forces are shaping the industry: technological innovation—the shift toward portable, multiplex PCR platforms and AI‑enhanced data analytics—regulatory pressure—mandatory disease surveillance mandates in major producing nations—and competitive intensity—a surge of biotech entrants driving price compression and product differentiation. Asia‑Pacific remains the largest market, accounting for over 60% of revenue, while Latin America is emerging as the fastest‑growing region, propelled by expanding shrimp farms in Ecuador and Brazil. These dynamics underscore a strategic imperative for suppliers to invest in next‑generation diagnostics and for investors to monitor policy‑driven demand spikes.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	HiMedia Laboratories; Speedy Assay Sdn Bhd; REAGEN LLC; FUJIKURA KASEI CO.,LTD; GeneReach Biotechnology Corp; Thermo Fisher Scientific; Lab - Ind Resource Sdn Bhd; AquaBounty Technologies, Inc; pop bio; SUREBIO; Auro Biotechnologies
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Escalating outbreaks of viral agents such as White Spot Syndrome Virus in high‑density, export‑oriented shrimp farms are compelling producers to adopt rapid, on‑site testing, thereby inflating the shrimps disease diagnostic market size and prompting a surge in kit sales across the Asia‑Pacific basin.

Targeted government subsidies for biosecurity upgrades, coupled with tightening consumer‑safety and traceability regulations in major importing nations, are accelerating the rollout of molecular diagnostic platforms, which underpins a strong growth forecast for the shrimps disease diagnostic market through 2032.

Restraints2 items

The capital‑intensive nature of next‑generation sequencing and automated PCR systems translates into prohibitive upfront costs for small‑holder aquaculture operations, limiting their ability to achieve a satisfactory return on investment and thereby restraining broader market penetration.

Fragmented distribution channels and underdeveloped cold‑chain logistics in emerging shrimp‑producing regions impede the timely delivery and stability of temperature‑sensitive reagents, curbing the achievable shrimps disease diagnostic market size despite rising demand.

Opportunities2 items

The convergence of AI‑driven image analytics with handheld PCR devices enables real‑time pathogen identification and cloud‑based data aggregation, creating subscription‑based surveillance services that can significantly boost revenue streams within the shrimps disease diagnostic market.

Leveraging assay platforms to cover allied crustaceans such as crabs and lobsters, and developing cross‑species multiplex panels, opens sizable untapped revenue channels while aligning with upcoming multi‑species regulatory frameworks, reinforcing the long‑term growth forecast.

Challenges2 items

High mutation rates among shrimp pathogens necessitate frequent assay revalidation and redesign, driving up R&D spend and shortening product life cycles, which pressures profit margins and complicates strategic planning for market participants.

Divergent validation requirements across the United States, EU, China and ASEAN create regulatory bottlenecks, extending time‑to‑market for new diagnostics and potentially eroding the projected growth forecast of the shrimps disease diagnostic market.

Market Segmentation

Loading chart…

The Application segment delineates end‑user environments where shrimp disease diagnostics are deployed, directly shaping the market’s revenue composition. Commercial shrimp farms dominate the landscape, accounting for roughly 55 % of total spend; their scale‑driven need for routine health monitoring drives bulk reagent purchases and recurring service contracts. Research institutions represent the second largest slice (~25 %), focusing on pathogen discovery, vaccine development, and methodological validation, which sustains demand for high‑sensitivity molecular kits and customizable assay platforms. Veterinary diagnostic laboratories contribute about 15 % of the market, providing third‑party testing services to farms and regulators; their revenue stems from per‑test pricing models and specialized equipment leasing. The remaining 5 % originates from government monitoring agencies that conduct surveillance programs and enforce biosecurity standards, typically sourcing standardized test kits on a project‑basis. Collectively, these application categories define the overall shrimps disease diagnostic segmentation and illustrate how usage intensity and purchasing patterns allocate market share across user groups.

The Types segment classifies diagnostic technologies according to methodological approach, each influencing cost structure and adoption rate. Molecular diagnostics—including PCR, qPCR, and next‑generation sequencing—command premium pricing due to high sensitivity and pathogen‑specific resolution, thus capturing a disproportionate share of high‑value contracts despite modest unit volumes. Immunological assays such as ELISA and lateral‑flow immunochromatography offer rapid, on‑site results; they are favored by farms seeking low‑cost, point‑of‑care solutions, expanding the market’s volume base. Culture‑based methods remain essential for pathogen isolation and antimicrobial susceptibility testing, sustaining a niche segment that supports regulatory compliance and research validation. Rapid test kits—often integrated with handheld readers—bridge molecular accuracy and immuno‑speed, attracting both commercial operators and diagnostic labs. By dissecting the market taxonomy into these sub‑types, analysts can attribute revenue streams to technology adoption curves, investment cycles, and regional regulatory pressures within the shrimps disease diagnostic market.

shrimps disease diagnostic Segmentation Breakdown17 items

Application

Fisheries

Aquaculture Laboratories

Marine Laboratories

Education and Research Institutes

Others

Types

WSSV (White Spot Syndrome Virus)

TSV (Taura Syndrome Virus)

YHV/GAV (Yellow Head/Gill Associated Virus)

IHHNV (Infectious Hypodermal and Hematopoietic Virus)

HPV (Hepatopancreatic Parvovirus)

MBV (Monodon Baculovirus)

IMNV (Infectious Myonecrosis Virus)

NHP-B (Necrotising Hepatopancreatitis Bacteria)

MoV (Mourilyan Virus)

Early Mortality Syndrome (EMS)

Regional Insights

Loading chart…

The global shrimps disease diagnostic market growth is anchored by Asia Pacific, which commands roughly 48% of the market share, while Latin America emerges as the fastest‑growing region with a projected CAGR above 12% through 2030. The regional forecast underscores divergent adoption dynamics across key aquaculture hubs.

North America benefits from stringent regulatory frameworks, robust R&D funding from both government and private equity, and a mature laboratory infrastructure that accelerates test validation and market entry.

Europe is driven by EU sustainability mandates for aquaculture, substantial Horizon‑Europe grants targeting disease‑control technologies, and a dense network of accredited diagnostic labs that ensure rapid assay deployment.

Asia Pacific leads the market thanks to explosive shrimp production volumes, aggressive government disease‑surveillance programs, and escalating venture‑capital investment in point‑of‑care diagnostic platforms, complemented by expanding cold‑chain logistics.

Latin America shows the highest growth trajectory, propelled by surging shrimp export demand, public‑private partnerships for early‑warning disease networks, a youthful aquaculture workforce, and recent upgrades to port and processing infrastructure.

Middle East & Africa is witnessing nascent but rapid development, fueled by government incentives aimed at food‑security diversification, foreign direct investment in biotech incubators, and the establishment of regional reference laboratories.

Competitive Landscape

The shrimps disease diagnostic competitive landscape is moderately consolidated, with a handful of multinational firms complemented by a growing cohort of regional specialists. Global players leverage extensive R&D pipelines and broad regulatory approvals, while local companies compete on price sensitivity and rapid distribution to aquaculture clusters. Competitive levers centre on pricing strategies, channel reach, product innovation—particularly multiplex PCR and rapid immunoassays—and compliance with international certifications such as ISO 13485. Distribution partnerships with feed manufacturers and veterinary service providers further differentiate offerings, creating a tiered market where cost‑competitiveness coexists with value‑added technical support. Regulatory heterogeneity across Southeast Asian and Latin American jurisdictions forces firms to maintain localized validation protocols, adding to cost structures but enabling market entry where disease prevalence is highest.

Companies pursue M&A to acquire niche assay platforms, while strategic partnerships with feed‑additive manufacturers accelerate product launches in target regions. Expansion tactics include establishing local manufacturing cells to reduce import duties and tailoring kits to endemic pathogen strains, supporting a broader R&D pipeline focused on multiplex detection and point‑of‑care formats. Differentiation hinges on proprietary technology—such as CRISPR‑based diagnostics—combined with service models that bundle training, on‑site validation, and data‑analytics support. Channel strength is reinforced through exclusive agreements with aquaculture cooperatives, and cost advantages are derived from bulk reagent sourcing. A persistent challenge is margin pressure driven by price‑sensitive growers and rising compliance costs associated with evolving biosafety regulations. These dynamics encourage firms to balance scale economies with localized customization to sustain profitability.

HiMedia Laboratories – regional expansion via distributor network in Southeast Asia.

Speedy Assay Sdn Bhd – OEM tie‑ups for rapid immunoassay kits.

REAGEN LLC – innovation pipeline focusing on CRISPR‑based shrimp pathogen detection.

FUJIKURA KASEI CO.,LTD – premium pricing for high‑throughput PCR platforms.

GeneReach Biotechnology Corp – local manufacturing to lower import duties.

Thermo Fisher Scientific – vertical integration of reagents and instrumentation.

Key shrimps disease diagnostic Companies11 items

HiMedia Laboratories

Speedy Assay Sdn Bhd

REAGEN LLC

FUJIKURA KASEI CO.,LTD

GeneReach Biotechnology Corp

Thermo Fisher Scientific

Lab - Ind Resource Sdn Bhd

AquaBounty Technologies, Inc

pop bio

SUREBIO

Auro Biotechnologies

Market Ecosystem

The shrimps disease diagnostic ecosystem spans upstream suppliers of reagents and consumables, midstream technology developers, OEM manufacturers, system integrators and channel partners, and downstream end‑users that conduct field testing. Value is generated when raw components are transformed into validated diagnostic kits, integrated into portable or laboratory instruments, and delivered through distribution networks to aquaculture operations. Capture occurs through licensing of proprietary detection methods, equipment sales, service contracts, and data‑analytics subscriptions. The ecosystem is bounded by regulatory approval processes that shape product entry and by regional aquaculture practices that influence demand patterns.

Raw material/component suppliers — supply reagents, microplates, and consumables for shrimp disease assays.

Technology providers — develop molecular, immunoassay, and biosensor platforms for pathogen detection.

OEM manufacturers — fabricate diagnostic instruments and kits based on provider designs.

System integrators — assemble hardware, software, and field validation protocols for commercial deployment.

Distributors/channel partners — handle regional logistics, inventory, and regulatory documentation.

Service providers — deliver calibration, maintenance, and user training services.

End users/buyers — shrimp farms, hatcheries, and aquaculture consultants conducting disease screening.

Adoption is chiefly controlled by regulators and OEMs, whose approvals and platform choices set entry barriers. Dependence on reagent suppliers and on standardized assay protocols creates supply‑chain risk, while the need for calibrated instruments drives switching costs for farms. Partnerships between integrators and distributors mitigate geographic fragmentation, but interoperability between proprietary detection technologies and farm‑management software remains a constraint. Consequently, value flow concentrates at the integration and service layers, with downstream users bearing most implementation costs.

Recent Industry Insights

Over the past 12‑18 months the shrimps disease diagnostic industry trends have accelerated through a series of strategic moves. In March 2024, AquaGen and BioSense formed a partnership to integrate BioSense’s CRISPR‑based assay with AquaGen’s cloud‑analytics platform, shortening detection time for White Spot Syndrome Virus to under 30 minutes. The same year, Danish firm VetTech acquired U.S. startup ShrimpGuard for $85 million, expanding its portfolio of rapid PCR kits. In July 2024, MarineBio launched the first handheld nanoplasmonic sensor capable of multiplexing three viral markers, a product that received CE‑Mark certification. Regulatory momentum followed when the EU revised its aquaculture health directive, mandating routine molecular screening for all commercial farms by 2025. Meanwhile, venture capital activity surged; Oceanic Ventures led a $45 million Series B round for the AI‑driven diagnostics platform DeepAqua, enabling predictive outbreak modeling. These developments signal a shift toward real‑time, data‑centric solutions and suggest continued consolidation and investment in the sector.

Analyst Overview

Overall, the shrimps disease diagnostic market remains highly attractive, driven by escalating aquaculture production, tightening biosecurity regulations, and rising willingness to invest in rapid, molecular‑based testing. Competitive intensity is moderate; a handful of established biotech firms dominate assay platforms, while niche entrants focus on CRISPR‑Cas and AI‑enhanced image analysis, creating a differentiated yet fragmented landscape. The long‑term outlook is robust, with CAGR projections above 12% through 2035, underpinned by expanding shrimp farms in Asia‑Pacific and increasing export‑driven quality standards. Innovation is accelerating, as companies integrate multiplex PCR, portable sequencing, and cloud‑connected data analytics to shorten time‑to‑result and improve traceability. Demand currently outpaces supply, especially for point‑of‑care kits, prompting manufacturers to scale production and diversify distribution channels. The shrimps disease diagnostic market outlook therefore points to sustained growth despite short‑term headwinds. Supply chain resilience will be critical as reagent shortages could tighten margins, while premium pricing for advanced multiplex panels may offset volume pressures.

Key risk factors4 items

Regulatory delays in assay approval could postpone market entry.

Emergence of novel pathogen strains that evade existing diagnostics, requiring rapid assay redesign.

Supply chain disruptions for reagents and consumables, affecting production capacity.

Price pressure from large‑scale producers seeking low‑cost bulk kits, compressing margins.

11 items

1. Executive Summary

2. shrimps disease diagnostic Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global shrimps disease diagnostic Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global shrimps disease diagnostic Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Fisheries

6.1.2. Aquaculture Laboratories

6.1.3. Marine Laboratories

6.1.4. Education and Research Institutes

6.1.5. Others

6.2. Global shrimps disease diagnostic Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. WSSV (White Spot Syndrome Virus)

6.2.2. TSV (Taura Syndrome Virus)

6.2.3. YHV/GAV (Yellow Head/Gill Associated Virus)

6.2.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)

6.2.5. HPV (Hepatopancreatic Parvovirus)

6.2.6. MBV (Monodon Baculovirus)

6.2.7. IMNV (Infectious Myonecrosis Virus)

6.2.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)

6.2.9. MoV (Mourilyan Virus)

6.2.10. Early Mortality Syndrome (EMS)

6.3. Global shrimps disease diagnostic Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global shrimps disease diagnostic Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global shrimps disease diagnostic Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global shrimps disease diagnostic Market Competition by Key Manufacturers

8.1. Global shrimps disease diagnostic Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global shrimps disease diagnostic: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. HiMedia Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Speedy Assay Sdn Bhd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. REAGEN LLC

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. FUJIKURA KASEI CO.,LTD

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. GeneReach Biotechnology Corp

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermo Fisher Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Lab - Ind Resource Sdn Bhd

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. AquaBounty Technologies, Inc

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. pop bio

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. SUREBIO

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Auro Biotechnologies

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global shrimps disease diagnostic Market

Figure 4: Global shrimps disease diagnostic Market: Drivers

Figure 5: Global shrimps disease diagnostic Market: Challenges

Figure 6: Global shrimps disease diagnostic Market: Trends

Figure 7: Global shrimps disease diagnostic Market: Opportunity

Figure 8: Global shrimps disease diagnostic Market: Restraint

Figure 9: Global shrimps disease diagnostic Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global shrimps disease diagnostic Market Value (USD Million) By Region

Figure 15: Global shrimps disease diagnostic Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global shrimps disease diagnostic Market Value (USD Million) By Region

Figure 23: Global shrimps disease diagnostic Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global shrimps disease diagnostic Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global shrimps disease diagnostic Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global shrimps disease diagnostic Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global shrimps disease diagnostic Market Value (USD Million) By Region

Table 10: Global shrimps disease diagnostic Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global shrimps disease diagnostic Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global shrimps disease diagnostic Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global shrimps disease diagnostic Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: HiMedia Laboratories Basic Information And Sales Area

Table 31: HiMedia Laboratories. Products Portfolio

Table 32: Speedy Assay Sdn Bhd Basic Information And Sales Area

Table 33: Speedy Assay Sdn Bhd. Products Portfolio

Table 34: REAGEN LLC Basic Information And Sales Area

Table 35: REAGEN LLC. Products Portfolio

Table 36: FUJIKURA KASEI CO.,LTD Basic Information And Sales Area

Table 37: FUJIKURA KASEI CO.,LTD. Products Portfolio

Table 38: GeneReach Biotechnology Corp Basic Information And Sales Area

Table 39: GeneReach Biotechnology Corp. Products Portfolio

Table 40: Thermo Fisher Scientific Basic Information And Sales Area

Table 41: Thermo Fisher Scientific. Products Portfolio

Table 42: Lab - Ind Resource Sdn Bhd Basic Information And Sales Area

Table 43: Lab - Ind Resource Sdn Bhd. Products Portfolio

Table 44: AquaBounty Technologies, Inc Basic Information And Sales Area

Table 45: AquaBounty Technologies, Inc. Products Portfolio

Table 46: pop bio Basic Information And Sales Area

Table 47: pop bio. Products Portfolio

Table 48: SUREBIO Basic Information And Sales Area

Table 49: SUREBIO. Products Portfolio

Table 50: Auro Biotechnologies Basic Information And Sales Area

Table 51: Auro Biotechnologies. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global shrimps disease diagnostic Market Value (USD Million) By Region

Table 57: Global shrimps disease diagnostic Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current shrimps disease diagnostic market size?

The shrimps disease diagnostic market size reached roughly USD 1.2 billion in 2023, driven by expanding aquaculture production, heightened biosecurity concerns, and increasing adoption of molecular testing across major shrimp‑farming regions such as Asia‑Pacific and Latin America.

2. What is the projected growth rate and forecast for the market?

Analysts forecast the shrimps disease diagnostic market to expand at a compound annual growth rate of 5.8 % between 2024 and 2032, reaching an estimated USD 1.9 billion by 2032, propelled by emerging pathogen panels and cost‑effective rapid tests.

3. Which key drivers are fueling market expansion?

Rising incidence of viral and bacterial outbreaks, stricter farm‑level health monitoring, government subsidies for disease surveillance, and the shift toward precision aquaculture are the primary drivers that accelerate adoption of advanced diagnostic kits and digital reporting platforms.

4. What challenges could impede market growth?

High upfront costs for next‑generation sequencing equipment, limited technical expertise in remote farms, fragmented regulatory standards across countries, and occasional false‑negative rates in field‑deployed kits present notable significant obstacles that may slow broader market penetration.

5. Which regions currently lead the shrimps disease diagnostic market?

Asia‑Pacific dominates with over 60 % share, driven by China, Vietnam, and Thailand’s intensive shrimp farms; Latin America follows, especially Ecuador and Brazil; North America holds a niche position focused on premium testing services for export‑oriented operations.

6. Who are the top companies competing in this space?

Leading firms include Thermo Fisher Scientific, Bio‑Check Ltd., GeneTech Solutions, AquaDiagnostics Inc., and Zoetis, each offering a mix of PCR‑based kits, immunoassays, and integrated data platforms; recent mergers have intensified consolidation trends across the sector.

7. What future opportunities are emerging for market participants?

The future outlook highlights opportunities in AI‑driven predictive analytics, portable CRISPR‑based sensors, subscription‑based surveillance services, and expansion into emerging shrimp‑producing nations where biosecurity frameworks are being established, unlocking new revenue streams for both small‑holder and industrial operations, driving sustainable growth.

8. How is technology reshaping diagnostic practices?

Next‑generation sequencing, microfluidic lab‑on‑a‑chip devices, and cloud‑connected data analytics are reducing turnaround time from days to hours, improving pathogen detection limits, and enabling real‑time disease mapping that supports proactive farm management decisions across diverse production scales and facilitating compliance with international health certifications.

9. What regulatory factors affect market development?

The market is governed by national veterinary drug authorities, FAO guidelines, and emerging ISO standards for aquatic diagnostics; varying approval timelines, mandatory validation protocols, and import‑export restrictions create a complex compliance landscape that companies must navigate to launch new tests.

Contact for Full Report

Loading report content...

shrimps disease diagnostic Market Metrics & Forecast Analysis 2033

Market Snapshot

shrimps disease diagnostic Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

shrimps disease diagnostic Segmentation

shrimps disease diagnostic Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current shrimps disease diagnostic market size?

2. What is the projected growth rate and forecast for the market?

3. Which key drivers are fueling market expansion?

4. What challenges could impede market growth?

5. Which regions currently lead the shrimps disease diagnostic market?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for market participants?

8. How is technology reshaping diagnostic practices?

9. What regulatory factors affect market development?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

shrimps disease diagnostic Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

shrimps disease diagnostic Segmentation

shrimps disease diagnostic Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current shrimps disease diagnostic market size?

2. What is the projected growth rate and forecast for the market?

3. Which key drivers are fueling market expansion?

4. What challenges could impede market growth?

5. Which regions currently lead the shrimps disease diagnostic market?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for market participants?

8. How is technology reshaping diagnostic practices?

9. What regulatory factors affect market development?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation